Ocutrx Vision Technologies Unveils Groundbreaking Oculenz AR Cellular with Eye-Tracking Glasses Design
New Aesthetic Design Provides Unprecedented Technology and Functionality in the AR Wear Industry
BARCELONA, Spain, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Ocutrx Vision Technologies, LLC, a California-based manufacturer of augmented reality (AR) glasses, today announced a new, state-of-the-art design for the company’s flagship Oculenz™ AR Wear glasses. The new aesthetic was co-developed by the award-winning product design team at Karten Design and is being unveiled at Mobile World Congress in Barcelona, the largest mobile and wearables event in the world.
Ocutrx’s redesigned, cutting-edge Oculenz AR glasses are low-profile and more lightweight (200 grams/.44 pounds) than the HoloLens 2 (566 grams/1.25 pounds) with floating lenses which provide a bright, unobstructed field of view complimenting the uniquely wide micro-display projection capacities—ideal for demanding medical applications, industrial environments and consumer use. The first market is for patients with macular degeneration and other low vision conditions.
Ocutrx is the first heads-up AR company to fully integrate eye-tracking and cellular connectivity into its headset design. The Oculenz AR Wear features eye-tracking cameras and IR illumination mounted in a streamlined nose bridge which provides clear line-of-sight to the eye without obstructing the user’s field of view. This centralized component design makes the Oculenz easily adapted to different augmented reality applications.
“We are pleased to work with Karten Design (www.kartendesign.com) on the all-new Oculenz AR glasses with onboard eye-tracking. This new cellular-connected AR Wear design isn’t just a step forward for Ocutrx, but rather for the entire AR Wear industry,” said Michael H. Freeman, CEO/CTO at Ocutrx. “For example, a surgeon in the operating room will now benefit from the feather light weight and redesigned head strap that provides comfort for extended periods of use and keeps the headset secure as the physician leans forward during surgery for 3D visualization. Additionally, the intuitive flip up display provides protection for industrial wear applications during nonuse.”
The Oculenz AR glasses will be of particular value for patients living with age-related macular degeneration (AMD). The eyeglass inspired design helps to relieve the stigma common with worn medical products and a tinted upper lens helps to visually obscure the SLAM sensors and 4K cameras embedded in the glasses. The headset is supported from the front and rear of the skull, providing comfort for extended periods of use. Additionally, the glasses are designed with pinch adjustment functionality on the rear head pad to allow for easy and intuitive resizing.
“At Karten Design, we create extraordinary experiences in healthcare by understanding the needs of consumers, patients, caregivers and clinical professionals,” said Stuart Karten, President/Founder of Karten Design. “We wanted the Oculenz design to inspire patients on an emotional level to enable better health outcomes. We worked to transform Ocutrx’s technology into a more appealing product that enables people to manage their low vision effectively while leveraging the technology and core design for applications in multiple industries."
Jordan Boss, the chief product engineer for Ocutrx who worked closely with the Karten Design team to build the exacting design, said, “As a millennial, I see how the AR fourth screen will soon become as ubiquitous to our generation as the smartphone was to the last. With cellular and WiFi connectivity and this easy-to-wear and use design, Oculenz will become the “smart-phone” of the future—and replace smart-phones like they replaced corded home phones, car phones and flip phones.”
MWC Barcelona (formerly Mobile World Congress) brings together the latest innovations and leading-edge technology from more than 2,400 leading companies, with a highly-rated conference program assembling today’s visionaries to explore the hottest topics influencing the industry.
With corporate headquarters in Irvine, California, and a research and development lab in the US Midwest, Ocutrx is a new breed of AR manufacturing company focusing on the best connected lightest weight AR headset housing the largest field-of-vision in the market. At a time when worldwide applications for easy-to-wear and easy-to-use AR solutions are being touted as the “next big thing after smartphones,” Ocutrx is creating impactful, revolutionary AR wear for mass use. To learn more about Ocutrx and its ground-breaking technology, please visit the company website at http://www.oculenz.com/.
Bastion Elevate (for Ocutrx Vision Technologies)
949-502-6200 ext. 224
Photos accompanying this announcement are available at:
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Standard Lithium Announces Closing of $11.4 Million Bought Deal Including Partial Exercise of Over-Allotment Option21.3.2019 14:00:00 CET | Pressemelding
VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L) is pleased to announce that it has closed its previously announced bought deal offering (the “Offering”), including the partial exercise of the over-allotment option. A total of 11,390,500 units (the “Units”) of the Company were issued at a price of $1.00 per Unit for gross proceeds of $11,390,500. Each Unit is comprised of one common share and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company at an exercise price of $1.30 per share, subject to adjustment in certain events, until March 21, 2022. The Units were offered and sold by way of a short form prospectus filed in each of the provinces of Canada, excluding Quebec, and offered and sold elsewhere outside of Canada on a private placement
NexOptic Appoints Rich Geruson, Former Lexmark CEO, to Board of Directors21.3.2019 14:00:00 CET | Pressemelding
VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- NexOptic Technology Corp. ("NexOptic" or the "Company") (TSX VENTURE: NXO) (OTCQX: NXOPF) (FRANKFURT: E3O1) is pleased to announce that Richard J. (Rich) Geruson has joined its Board of Directors, effective immediately. Mr. Geruson’s experience spans CEO roles at Lexmark International, Phoenix Technologies and VoiceSignal Technologies, and Senior Vice President and executive positions at Nokia, IBM, Toshiba, and McKinsey & Co. As CEO of Lexmark International, a multibillion-dollar imaging technology and solutions company with 10,000 employees, he grew printer sales faster than at any time in the preceding 10 years while simultaneously executing extensive process reengineering, transforming the business from negative EBITDA and high debt to positive multi-hundred-million-dollar EBITDA and a healthy debt profile. While CEO of Phoenix Technologies, he achieved consistently high profit year-over-year for six years straight in
Crown Bioscience to Present Latest Advancements in Preclinical and Translational Platforms at AACR Annual Meeting 201921.3.2019 13:30:00 CET | Pressemelding
15 posters present data from novel models to evaluate new cancer therapeutics SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the presentation of 15 scientific posters at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA from March 29 to April 3. The scientific posters highlight the latest advancements in CrownBio’s integrated oncology and immuno-oncology platforms built on the world’s largest and unique experimental model libraries, including patient-derived xenografts (PDXs), innovative humanized mouse models, GEMM, syngeneic mouse tumor homografts, PDX derived organoids (PDXO), and uniquely developed analytic methods. Featured posters will present data from novel models that enable detailed evaluation of new cancer therapeutics, including targeted cancer i
Teledyne CARIS software selected to enable major government project in Africa21.3.2019 12:00:00 CET | Pressemelding
FREDERICTON, New Brunswick, March 21, 2019 (GLOBE NEWSWIRE) -- Teledyne CARIS™ is pleased to announce they will be delivering a full software solution to the South African Navy Hydrographic Office. The solution, provided through Teledyne CARIS’ official distributor Unique Group, includes software that will be implemented as part of a larger project to be executed by Southern African Shipyards (SAS) where a new hydrographic survey vessel is being built. Three additional survey motor boats are also slated for manufacture, all of which will be equipped with HIPS and SIPS™ to process acquired hydrographic data. During the project, the shore based South African Navy Hydrographic Office will be refurbished and Bathy DataBASE™ (BDB) and Hydrographic Production Database™ (HPD) will be implemented to manage hydrographic data and produce nautical products like paper charts, ENCs and other digital products. The implementation phase is set to commence shortly, and will begin with the installation
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease21.3.2019 12:00:00 CET | Pressemelding
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. The decision to stop the trials is based on results of a futility analysis conducted by an independent data monitoring committee, which indicated the trials were unlikely to meet their primary endpoint upon completion. The recommendation to stop the studies was not based on safety concerns. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience. We are incredibly grateful to all the Alzheimer’s disease pa
DATE 2019: eSilicon to present two papers on advanced floor planning techniques with the Polytechnic University of Catalonia21.3.2019 01:35:00 CET | Pressemelding
BARCELONA, Spain, March 20, 2019 (GLOBE NEWSWIRE) -- What: eSilicon, a leading provider of FinFET-class ASICs, market-specific IP platforms and advanced 2.5D packaging solutions, with the Polytechnic University of Catalonia, Barcelona, Spain are presenting two papers on advanced floor planning techniques at DATE 2019, Florence, Italy. Who: Alex Vidal-Obiols, Jordi Cortadella, Jordi Petit, Department of Computer Science, Universitat Politècnica de Catalunya. Marc Galceran-Oms, Ferran Martorell, eSilicon EMEA, Barcelona, Spain. RTL-Aware Dataflow-Driven Macro Placement This paper proposes a novel multi-level approach for macro placement of complex designs dominated by macro blocks, typically memories. Using the hierarchy tree, the netlist is divided into blocks containing macros and standard cells and their dataflow affinity is inferred considering the latency and flow width of their interaction. This information, known by the RTL designer, is often lost during physical synthesis. The la